๐ฐ French Commercial Code News
Page 44 - French Commercial Code News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from French Commercial Code. Real-time updates on events, politics, business and more.
May 10, 2023
PROPOSED RESOLUTIONS 2023 GENERAL MEETING Proposed resolutions and explanatory statements ... | May 10, 2023
May 10, 2023
Kaufman & Broad SA Kaufman & Broad SA: RESULT OF VOTES OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS MEETING OF MAY 4, 2023 10-May-2023 / 17:20 CET/CEST Dissemination of a French... | May 10, 2023
May 10, 2023
DJ Kaufman & Broad SA: RESULT OF VOTES OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF MAY 4, 2023 Kaufman & Broad SA Kaufman & Broad SA: RESULT OF VOTES OF THE ORDINARY AND EXTRAORDINARY
May 10, 2023
Availability of preparatory documents for the Annual General Meeting of May 31, 2023 Paris, May 10, 2023 - The shareholders of Deezer are... | May 10, 2023
May 10, 2023
France 6 boulevard Bineau 562 088 542 R.C.S. NANTERRE PRIOR NOTICE OF MEETING CONSTITUTING A NOTIFICATION TO ATTEND ... | May 10, 2023
May 10, 2023
10.05.2023 - Rexel: Statement relating to the total number of shares and voting rights pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Rules of the French Autoritรฉ des marchรฉs financiers DateNumber of sharesNumber ...
May 10, 2023
10.05.2023 - INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL In Bernin, on May 10, 2023 (Article L. 233-8 II of the French Commercial Code and article 223-16 of the General Regulation of the French financial ...
May 9, 2023
May 9, 2023 Vantiva: Information concerning the total number of voting rights and shares, provided pursuant to Article L. 233-8 II of the French...
May 9, 2023
InformationMay 9, 2023 Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés... | May 9, 2023
May 9, 2023
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including